In this area you will be able to:
- Propose, vote on, and discuss research ideas
- View current studies
- View published research
Here, you can submit a research idea to the community, cast your votes, and discuss research ideas proposed by other members. Please make your research question as specific as possible. Other members will vote on your research idea, and we will prioritize research ideas with the most votes.
You are allowed to vote for your own proposed research idea if you want. However, you can only vote for a total of five research ideas. If you have already cast your five votes and an idea you like even more is proposed, you can change your votes at any time to reflect your current preferences.
The research team will review all submitted ideas and provide a response to you and to the community. If your idea leads to an IBD Partners Study, you will have the opportunity to serve as a patient collaborator on the research team for that study.
We encourage you to prioritize the ideas that are most important to you, even if the research team determines that your idea is not a good fit for IBD Partners. We will share ideas labeled “Not a Good Fit” with researchers outside of our network when appropriate. We want to make sure all of your votes count!
Thanks for your participation in this important platform to help the IBD research community understand what research questions are important to patients. We are passionate about finding answers to your questions!
What is unique about the histology and/or immunology of fistulas that limit their response to current immunomodulator therapies?
None of the currently approved or clinical stage immunotherapies for IBD have shown to offer substantive benefits in the improvement or healing of fistulas. This is continues to be a significant gap in the non-surgical treatment of fistulizing disease.
I propose to look at the incidence of periodontal disease in IBD patients, and to examine if there is any correlation to the disease itself, or to medications used for disease control.
Anecdotally, there seems to be a positive correlation; however, hard data seems non-existent. With the known relationship between periodontal disease and heart disease, it would be important for IBD patients to know if this is an issue they need to stay on top of.
What is the nutritional impact (loss of nutrients) which a person with IBD (Ulcerative Colitis) experiences when their Colitis is in remission.
I have been in remission for 6 years, yet I seem to not be absorbing Potassium, producing Vitamin D - even though I work outdoors year round in a city that claims 360 days of sunshine, and seem to not be absorbing several other minerals. I suffer from chronic continuous calcium oxalate kidney stones due to calcium binding with oxalate instead of magnesium citrate or potassium citrate. The nutritional absorption in the colon would be especially useful for drs to treat patients like me as medication absorption also seems to be an issue.
Can there be a data study (or is there one in progress) to find out what percentage of people have had to go off of different IBD medications because of contracting COVID and needing to boost immune?
I am very scared that if I contract covid I will have to go off of my medication which I have worked so hard to fit to my disease and help stabilize my symptoms. I believe many others are feeling this way right now.
Do changes in manufacturing processes of Biologics alter the clinical impact (treatment success and/or adverse events)?
Biologic medications are developed through a complex process of using living organisms to harvest the biologic proteins. Manufacturers sometimes alter the manufacturing process, and these changes have the potential to cause slight changes in the final product. There is a lack of data/research regarding the impact of these slight changes. Furthermore, biosimilars (biologics developed by new manufacturers with different manufacturing processes), are pending FDA approval. Biosimilars will not require as extensive clinical testing prior to approval, compared with the original manufactured products. We ought to collect extensive data to better understand if slight changes in biologic proteins have a clinical impact.
Develop nutritionally sound and bio-available nutritional supplement(s) addressing long term health issues associated with poor vitamin/ mineral/ nutrient absorption due to rapid transit time, medication and/ or scarring of the intestinal lining.
Long term chronic IBD often includes development of nutritional deficiencies due to diet, eating patterns, medication side effects and intestinal scarring which are difficult to overcome using traditional supplements due to low bio-availability, supplement form, difficulty incorporating into liquid, soft or normal diet, nutritional completness.
There is a significant population of patients for whom biologics are no longer a viable or recommended treatment. Our healthcare going forward is complicated by the permanent effects of these medications on the body's systems.
Compare medications taken (and other medical conditions experienced) by IBD patients BEFORE symptoms of IBD began to greater understand causes of the disease.
Prevention is the best medicine!
Is saccharomyces boulardii a possible alternative for many of the medications currently used for UC and Crohns?
I think this research is very important given the cost of medication currently prescribed for these illnesses not to mention the many side effects these drugs can have on a person's overall health.
Are biosimilars equally effective maintaining remission in patients who achieved remission with the “brand” TNF-blocker?
I was at a recent CCF educational session and the gastroenterologist giving a talk said that VA patients, stable on infliximab, were switched to the biosiomilar, presumably for cost. Some did not do was well after the switch. If someone is stable on a TNF-blocker, what is the risk of their illness worsening if switched to the biosimilar?
Diet Low in Red and Processed Meat Does Not Reduce Rate of Crohn’s Disease Flares
Paternal Disease Activity Is Associated With Difficulty in Conception Among Men With Inflammatory Bowel Diseases